Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine

Cancer Epidemiology Biomarkers and Prevention

Volumn 9, Issue 11, 2000, Pages 1155-1162

  Lawson, Kathryn R ^a   Ignatenko, Natalia A ^c   Piazza, Gary A ^e   Cui, Hiayan ^d   Gerner, Eugene W ^a,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b Departments of Radiation Oncology   (United States)

^c Arizona Cancer Center ^*

^d Departments of Biometry   (United States)

^e Cell Pathways Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; EFLORNITHINE; SULINDAC;

APOPTOSIS; ARTICLE; CANCER PREVENTION; CELL KINETICS; CELL STRAIN CACO 2; CELL SURVIVAL; CELL VIABILITY; CHEMOPROPHYLAXIS; COLON CANCER; COLON CARCINOGENESIS; CYTOTOXICITY; GENE ACTIVATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; ONCOGENE K RAS; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CACO-2 CELLS; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CHEMOPREVENTION; EFLORNITHINE; ENZYME INHIBITORS; GENES, RAS; HUMANS; SULINDAC;

EID: 0033729960     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Genetic alterations during colorectal tumor development
2. Mutations in the K-ras2 oncogene during progressive stages of human colon carcinoma
3. K-ras and p53 mutations in human colorectal aberrant crypt foci
4. Assessment of mutations in K-ras and p53 in colon cancers from azoxymethane- and dimethylhydrazine-treated rats
5. K-ras mutations in aberrant crypt foci adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis
6. Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis
7. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal anti-inflammatory drug with D, L-α-difluoromethylornithine, and ornithine decarboxylase inhibitor in diet
8. Modulation of azoxymethane-induced mutational activation of ras protooncogenes by chemopreventive agents in colon carcinogenesis
9. Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment
10. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels
11. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent
12. Molecular markers in chemoprevention of colon cancer. Inhibition of expression of ras-p21 and p53 by sulindac during azoxymethane-induced colon carcinogenesis
13. Inhibition of apoptosis during development of colorectal cancer
14. Prostaglandins, their inhibitors and cancer. Prostaglandins Leukotrienes Essent
15. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis
16. Nonsteroidal antiinflammatory drugs, eicosanoids, and colorectal cancer prevention
17. Mechanism of action of aspirin-like drugs
18. Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase?
19. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
20. Inhibition of mammary carcinogenesis by sulfone metabolite of sulindac
21. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway
22. Exisulind induction of apoptosis involves guanosine 3', 5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin
23. Intermediate biomarkers of colon cancer, modulation of expression of ras oncogene by chemopreventive agents during azoxymethane induced colon carcinogenesis
24. Effect of the chemopreventive agents piroxicam and D, L-α-difluoromethylornithine on intermediate biomarkers of colon carcinogenesis
25. Abnormal accumulation and toxicity of polyamines in a difluoromethylornithine-resistant HTC cell variant
26. Enhancement of the spermidine uptake system and lethal effects of spermidine overaccumulation in omithine decarboxylase-overproducing L1210 cells under hyposmotic stress
27. Mechanisms of spermine toxicity in baby-hamster kidney (BHK) cells
28. Loss of intracellular putrescine pool-size regulation induces apoptosis
29. Regulation of human ornithine decarboxylase expression by the c-myc max protein complex
30. The ornithine decarboxylase gene is a transcriptional target of c-Myc
31. Ornithine decarboxylase is a mediator of c-myc-induced apoptosis
32. Constitutive c-myc expression in an IL-3 dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis
33. Apoptosis: Its significance in cancer and cancer therapy
34. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
35. Increases protein kinase C α expression in human colonic Caco-2 cells after insertion of human Ha-ras or polyoma virus middle T oncogenes
36. Biological characterization and oncogene expression in human colorectal carcinoma cell lines
37. The human colon carcinoma cell lines HT-29 and Caco-2: Two in vitro models for the study of intestinal differentiation
38. Altered growth of human colon cancer cell lines disrupted at activated K-ras
39. Tumorigenic behaviour of c-Ha-ras oncogene transfected CaCo 2 cells is associated with increased proteolytic potency
40. 2-terminal kinase/stress-activated protein kinase or extracellular signal-regulated kinase activation in human colon cancer cells
41. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis
42. The stress-activated protein kinase pathways
43. Ras protein signaling
44. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
45. Modulation of apoptosis by sulindac, curcumin phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate, apoptotic index as a biomarker in colon cancer chemoprevention and promotion
46. A K-ras oncogene increases resistance to sulindac-induced apoptosis in rat enterocytes
47. A selective cyclooxygenase-2 inhibitor suppresses the growth of H-ras transformed rat intestinal epithelial cells
48. Sulindac sulfone inhibits cyclooxygenase-2 expression in human colon cancer cells expressing an activated k-ras oncogene
49. Effect of different levels of ω-3 and ω-6 fatty acids on azoxymethane-induced colon carcinogenesis a F344 rats